Prelude Therapeutics Stock Performance
| PRLD Stock | USD 0.71 0.03 4.05% |
The company holds a Beta of 2.4, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prelude Therapeutics will likely underperform. At this point, Prelude Therapeutics has a negative expected return of -0.72%. Please make sure to check Prelude Therapeutics' semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to decide if Prelude Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Prelude Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Acquisition by Andrew Combs of 60000 shares of Prelude Therapeutics at 1.3667 subject to Rule 16b-3 | 12/23/2024 |
2 | Acquisition by Vaddi Krishna of 10000 shares of Prelude Therapeutics at 1.2 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Vaddi Krishna of 5000 shares of Prelude Therapeutics at 1.2087 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Vaddi Krishna of 496000 shares of Prelude Therapeutics at 1.11 subject to Rule 16b-3 | 02/04/2025 |
5 | We Think Prelude Therapeutics Needs To Drive Business Growth Carefully | 03/04/2025 |
6 | Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 | 03/10/2025 |
7 | Acquisition by Vaddi Krishna of 47500 shares of Prelude Therapeutics at 0.7104 subject to Rule 16b-3 | 03/12/2025 |
8 | Acquisition by Vaddi Krishna of 50000 shares of Prelude Therapeutics at 0.7164 subject to Rule 16b-3 | 03/13/2025 |
9 | Acquisition by Vaddi Krishna of 29999 shares of Prelude Therapeutics at 0.7544 subject to Rule 16b-3 | 03/14/2025 |
10 | Insider Spends US70k Buying More Shares In Prelude Therapeutics | 03/19/2025 |
| Begin Period Cash Flow | 29.3 M |
Prelude |
Prelude Therapeutics Relative Risk vs. Return Landscape
If you would invest 124.00 in Prelude Therapeutics on December 23, 2024 and sell it today you would lose (53.00) from holding Prelude Therapeutics or give up 42.74% of portfolio value over 90 days. Prelude Therapeutics is currently does not generate positive expected returns and assumes 6.1753% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Prelude, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prelude Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prelude Therapeutics, and traders can use it to determine the average amount a Prelude Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1172
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRLD |
Estimated Market Risk
| 6.18 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.72 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Prelude Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prelude Therapeutics by adding Prelude Therapeutics to a well-diversified portfolio.
Prelude Therapeutics Fundamentals Growth
Prelude Stock prices reflect investors' perceptions of the future prospects and financial health of Prelude Therapeutics, and Prelude Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prelude Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (8.46) % | ||||
| Current Valuation | (76.37 M) | ||||
| Shares Outstanding | 42.3 M | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 5.60 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 7 M | ||||
| EBITDA | (139.71 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 2.38 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Earnings Per Share | (1.68) X | ||||
| Market Capitalization | 39.19 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
About Prelude Therapeutics Performance
By analyzing Prelude Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Prelude Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prelude Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prelude Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.76) | |
| Return On Capital Employed | (0.93) | (0.98) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (0.97) | (0.92) |
Things to note about Prelude Therapeutics performance evaluation
Checking the ongoing alerts about Prelude Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prelude Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics has some characteristics of a very speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 7 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Insider Spends US70k Buying More Shares In Prelude Therapeutics |
- Analyzing Prelude Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prelude Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Prelude Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prelude Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prelude Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prelude Therapeutics' stock. These opinions can provide insight into Prelude Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |